Gonadorelin

Generic Name: Gonadorelin

Brand Names: Lutrepulse

Drug Type: Small Molecule

Chemical Formula: C_₅₅H_₇₅N_₁₇O_₁₃

CAS Number: 33515-09-2

Unique Ingredient Identifier: 9O7312W37G

Background: Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.

Indication: For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.

Associated Conditions: -

Associated Therapies: Ovulation induction therapy

Clinical Trials

Administration of Kisspeptin in Patients With Hyperprolactinemia

Phase 2

Completed

Conditions: Hypogonadism
Hyperprolactinemia

Interventions: Drug: Kisspeptin 112-121
Drug: GnRH

First Posted Date: 2016-11-06

Last Posted Date: 2024-10-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT02956447

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome

Not Applicable

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: Gonadotropin-releasing Hormone

First Posted Date: 2016-03-10

Last Posted Date: 2016-03-10

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT02705014

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Reprometabolic Syndrome Mediates Subfertility in Obesity

Not Applicable

Completed

Conditions: Obesity
Infertility
Hypogonadotropic Hypogonadotropism
Hyperinsulinemia

Interventions: Drug: Insulin
Drug: Intralipid
Drug: Dextrose
Drug: GnRH
Drug: Heparin
Procedure: Hyperinsulinemic Euglycemic Clamp

First Posted Date: 2016-01-12

Last Posted Date: 2024-11-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 84

Registration Number: NCT02653092

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: Bicalutamide
Drug: Apalutamide
Drug: Bicalutamide Placebo
Drug: Apalutamide Placebo
Drug: GnRH (agonist)
Radiation: 74-80 Grays (units of radiation)

First Posted Date: 2015-08-24

Last Posted Date: 2025-01-09

Lead Sponsor: Aragon Pharmaceuticals, Inc.

Target Recruit Count: 1503

Registration Number: NCT02531516

GnRH for Luteal Support in IVF/ICSI/FET Cycles

Phase 4

Recruiting

Conditions: Infertility

Interventions: Drug: placebo
Drug: GnRH

First Posted Date: 2015-02-06

Last Posted Date: 2023-05-11

Lead Sponsor: University Reproductive Associates

Target Recruit Count: 350

Registration Number: NCT02357654

Locations: 🇺🇸
University Reproductive Associates, Hasbrouck Heights, New Jersey, United States

Neuropeptides in Human Reproduction

Phase 1

Completed

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: Kisspeptin 112-121
Drug: Naloxone
Drug: GnRH

First Posted Date: 2013-09-30

Last Posted Date: 2024-07-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 61

Registration Number: NCT01952782

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

Not Applicable

Completed

Conditions: Fertility
Obesity

Interventions: Dietary Supplement: LOVAZA
Drug: GnRH

First Posted Date: 2013-07-10

Last Posted Date: 2017-02-02

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 39

Registration Number: NCT01894581

Locations: 🇺🇸
University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States

Females, Aging, Metabolism, and Exercise

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: GnRH agonist
Behavioral: Supervised cardiovascular exercise

First Posted Date: 2012-10-23

Last Posted Date: 2019-11-22

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 47

Registration Number: NCT01712230

Locations: 🇺🇸
University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Phase 1

Completed

Conditions: Hypogonadotropic Hypogonadism
Agonadism
Healthy Postmenopausal Women

Interventions: Drug: kisspeptin 112-121
Drug: GnRH

First Posted Date: 2011-09-21

Last Posted Date: 2022-07-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 96

Registration Number: NCT01438073

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Kisspeptin in the Evaluation of Delayed Puberty

Phase 1

Completed

Conditions: Delayed Puberty
Hypogonadotropic Hypogonadism
Kallmann Syndrome
GnRH Deficiency

Interventions: Drug: kisspeptin 112-121
Drug: GnRH

First Posted Date: 2011-09-21

Last Posted Date: 2023-10-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 24

Registration Number: NCT01438034

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy